Inadequate Warnings Expand Onglyza MDL
Inadequate Warnings Expand Onglyza MDL
Introduction
A growing number of Onglyza lawsuits are fast becoming a part of MDL No. 2809 established in February for coordinated pretrial proceedings. AstraZeneca and Bristol Myers Squibb are the defendants named in this litigation. Cases have been coordinated in the U.S. District Court for the Eastern District of Kentucky under District Judge Karen K. Caldwell.
Recently, a lawsuit was filed in the U.S. District Court for the Eastern District of Kentucky by a plaintiff, who claims that the use of Onglyza and Kombiglyze XR led to the development of his heart failure and other related injuries, which could have been avoided if the drug makers had provided adequate warnings. His claim also details how the defendants continued to market Onglyza and Kombiglyze XR as safe and effective, in spite of being well aware of the heart failure risks.
Comments
Latest News
Study Links Roundup Chemical to Long-Term Brain Damage
Categories: Roundup
A recent study suggests that exposure to the widely used herbicide Roundup, which contains the active ingredient glyphosate, may be…
Zimmer Biomet Gets FDA Approval for Cementless Partial Knee
Categories: Zimmer Hip/Knee Replacement
Zimmer Biomet announced it has received supplemental FDA premarket approval (PMA) for the Oxford Cementless Partial…
Court Names Special Masters for Bard Mesh Claim Settlements
Categories: Hernia Mesh
The U.S. District Judge overseeing the federal litigation involving Bard hernia mesh lawsuits has appointed two…